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Abstract
Background: Patients with growth hormone deficiency (GHD) frequently report to suffer from
an impaired Quality of Life (QoL) and growth hormone (GH) substitution is found to improve this.
However, the same test may be used for measuring QoL, well-being or health status in different
studies. QoL has been defined as the subjective appraisal of one's current life based primarily on
psychological function. The most important in the appraisal of well-being is mental function and
concerning health status patients evaluate physical function as most important. To differentiate the
effects of GH replacement on psychological variables in patients with GHD we carried out a
number of meta-analyses, classifying questionnaires into instruments measuring QoL, psychological
well-being and health status.
Methods: We searched the electronic databases PUBMED and PiCarta from 1985 to 2004.
Studies were included that evaluated the effect of GH on patient-reported outcomes in adults with
GHD (aged 18 years and above). According to generally accepted definitions we classified the
questionnaires as instruments measuring QoL, well-being and health status. By means of meta-
analyses the average effect size (d) for QoL, well-being and health status was calculated.
Results and Discussion: Based on open studies GH replacement is found to improve QoL with
a small effect size (d = 0.18), well-being with a medium effect size (d = 0.47) and health status with
a small effect size (d = 0.26). As the effect size of well-being is most pronounced the generally
reported effects of GH replacement on QoL may be overestimated and actually reflect the effect
on well-being.
Conclusion: To get more insight in the specific psychological effects of GH treatment it is
recommended that instruments selected for these studies should be more consistently classified as
instruments measuring QoL, well-being or health status.
Background
The concept of Quality of life (QoL) is frequently used in
reports of studies in patients with growth hormone defi-
ciency (GHD). It is already 4 decades ago that the first
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mone deficiency. In this particular study the effect of GH
substitution on QoL in a GHD patient is described [1].
From then on, it has been frequently reported that
patients with GHD suffer from an impaired Quality of Life
(QoL), and that growth hormone (GH) substitution
improves their condition [2-6]. With regard to GHD, a
subnormal QoL in adults with GHD is inferred from the
observations that these patients feel less energetic, are
emotionally more labile, and experience disturbances in
sex life and feelings of social isolation at a significantly
higher frequency than controls [2,3,6,7]. With respect to
GH substitution in GHD adults, the effects of 10 years of
GH replacement on psychological well-being have been
evaluated. Overall scores for the NHP, energy levels and
emotional reaction improved in the GH-treated group
compared to an untreated group [8]. In addition, one year
of discontinuation of GH treatment in a study in GHD
patients led to a decrease in QoL (psychological com-
plaints and depression). This effect was counteracted after
restart of GH therapy resulting in reduced anxiety and
depression and improved QoL [9]. In another study with-
drawal of GH treatment from adults with GHD had detri-
mental psychological effects (decreased energy, increased
tiredness, pain, irritability and depression) [10]. The stud-
ies above exemplify that the psychological effects of GH
replacement are being measured with a variety of instru-
ments. Moreover, the same tests may be used as an instru-
ment measuring QoL in one and well-being or health
status in another study.
The concept of QoL with particular relevance to patients
with GH deficiency has been defined as "the social and
psychological well-being assessed from the patient's per-
spective". Elements which contribute to a person's QoL
are their levels of emotional, cognitive and social func-
tioning [11]. Indeed, it is generally acknowledged that the
QoL of a patient is not only defined by quantitative factors
of a disease, for example the severity of GH deficiency, but
also by psychosocial factors. Functional impairments, not
being able to perform personal goals, unemployment and
relational problems should also be taken into account
when measuring the influence of a disease for a patient
[12].
A decade ago editorial attention in the Lancet was paid to
the conceptual and methodological difficulties pertaining
to the concept of QoL [13]. This editorial included the
study of Gill and Feinstein [14] who sampled 75 articles
with "quality of life' in their titles. Only 15% of the sam-
ple included definitions of QoL and in only 13% of the
cases patient-rated QoL measures – as opposed to 'objec-
tive' questionnaires – were used. From the perspective of
patients, QoL and health status have been found to be dis-
tinct constructs. QoL has been defined as 'the subjective
appraisal of one's current life based primarily on psycho-
logical function and to a lesser degree on physical func-
tioning'. Indeed, when rating QoL, patients give greater
emphasis to mental health than to physical functioning.
This pattern is reversed for appraisal of health status, for
which physical function is more important than mental
health [15]. In a second commentary in the Lancet the
importance of differentiating health status from QoL is
also addressed. It is stated that using a health status ques-
tionnaire, which is measuring how people feel about their
health, to assess QoL may lead to misleading conclusions.
In case of health status patients report how they feel
mainly about their physical health, whereas in case of
reporting well-being patients exhibit feelings of depres-
sion, anxiety and energy [16]. Thus, patient reported out-
comes of physical status may be specifically measured by
a health status questionnaire such as the Short-form
Health Survey (SF-36) [17], whereas mental status may be
measured by a well-being questionnaire such as the Psy-
chological General Well-being Index (PGWB) [18]. It may
be clear that such generic measures of health status and
well-being are not measures of QoL, although often cate-
gorized as such. Therefore, with respect to the measure-
ment of QoL in patients with GHD, a few disease-specific
QoL questionnaires have been developed, the QoL-
AGHDA being one of these. This is a condition-specific
QoL measure. All items of this instrument are expressed as
unsatisfied needs [19]. More recently, the psychometric
properties of a new individualized questionnaire, the A-
RHDQoL, measuring perceived impact of age-related hor-
monal decline on QoL in older men, have been reported.
The questionnaire is individualized because respondents
only rate those domains that are relevant to them. Both
the impact of age-related hormonal decline on life
domains and the importance of each domain to the indi-
vidual are taken into account [10].
A complete picture of the effects of GH replacement on
psychological status in GHD patients can be inferred from
changes determined with a QoL scale, in conjunction with
an established measure of health status and another of
well-being. However, up until now these scales have not
been used consequently to measure specifically one of
these concepts. As a consequence, in spite of a number of
studies on the effects of GH treatment on psychological
status, the relative contribution of GH treatment on
changes in QoL, well-being and health status is not
known yet.
In order to differentiate the effects of GH replacement on
psychological variables in patients with GHD we carried
out a number of meta-analyses, distinguishing between
QoL, psychological well-being and health status.Page 2 of 7
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Search strategy
We searched the electronic databases PUBMED and
PiCarta from 1985 to 2004. PiCarta is an integrated mul-
timaterial database with request-facilities and offering
access to online resources and electronic documents.
Studies were included that evaluated the effect of GH on
patient-reported outcomes in adults with GHD (aged 18
years and above). The following search terms were used:
growth hormone, mood, health status, well-being and
quality of life.
Study selection
Two investigators independently examined manuscripts
for inclusion. Eligible studies were reports providing
quantitative data about the effect of GH therapy on
patient-reported outcomes in GH deficient adults. Studies
had to be placebo-controlled or designed as a cross-over/
parallel or open clinical trial. Questionnaires had to be
used to measure patient-reported outcomes. Case reports,
review articles and studies in which the psychometric
quality of the used questionnaire was unknown were
excluded. Furthermore, studies on GH therapy for other
diseases (for instance Turner syndrome, Prader Willi Syn-
drome, fibro-myalgia, etc.) were not included in this
meta-analysis.
Statistical analysis
We carried out a series of meta-analyses using a random
effects model. The meta-analyses were performed by
means of the statistical package Comprehensive Meta-anal-
ysis (Biostat, Inc, USA) [20]. This program is used to deter-
mine d-values (effect sizes). The most commonly used
measures of effect size are the standardized mean differ-
ence (d) and the correlation coefficient (r). The effect size
is a simple quantitative measure that provides one useful
index of the importance of an effect. The effect size index
d standardizes the raw effect size as expressed in the meas-
urement unit of the dependent variable by dividing it by
the common SD of the measures in their respective popu-
lations [21]. We calculated the difference prior to and after
GH therapy, divided by the pooled standard deviation of
the two measurements. Effect sizes (d's) were calculated,
averaged for each study and pooled. Effect size d = 0.2–0.5
is conceived as a small effect, d = 0.5–0.8 as a medium
effect and d ≥ 0.8 as a large effect. A medium effect size is
conceived as one large enough to be visible to the naked
eye [21].
Table 1: Classification of questionnaires into instruments measuring quality of life, psychological well-being or health status
Quality of Life • Qol Assessment of Growth Hormone Deficiency in Adults (QoL-
AGHDA)
• Satisfaction with physical activity (VAS-score)
• Sick leave, Hospital days, Doctor visits
• Nottingham Health Profile (NHP, part 1) scale: Physical mobility
• Quality of Life Scale (QLS)
• Life Fulfilment Scale
Psychological well-being • Psychological General Well-being Scale (PGWB), except General 
Health scale
• NHP scales: Emotional reactions, Social isolation, Energy.
• Minnesota Multiphasic Personality Inventory-2 (MMPI-2) scale: 
Depression.
• Hamilton Depression Scale (HDS).
• Beck Depression Inventory (BDI).
• Profile Of Mood States (POMS).
• Sjöberg mood questionnaire.
• State-Trait Anxiety Inventory (STAI) subscale: State anxiety.
• Kellner Symptom Questionnaire (KSQ).
• Symptom Checklist (SCL-90): Anxiety, Depression.
• Mental Fatigue Questionnaire (MFQ).
• Hospital Anxiety and Depression scale.
Health status • General health questionnaire (GHQ).
• NHP scales: Overall score, Pain, Sleep.
• PGWB scale: General health.
• Hopkins Symptom Checklist (HSCL).
• Leisure time physical activity (VAS-score)
• SCL-90 scale: Somatic complaints, Sleep.Page 3 of 7
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The most frequently encountered questionnaires measur-
ing QoL, well-being or health status encountered in the
studies included in the meta-analysis are described below.
The Nottingham Health Profile (NHP) is a frequently used
health status questionnaire in GH deficient patients that
measures physical, emotional and social distress. It con-
sists of the subscales emotional reactions, energy, pain,
physical mobility, sleep and social isolation [22]. The Psy-
chological General Well Being Schedule (PGWB) measures
self-perceived affective and emotional states [18]. Sub-
scales include anxiety, depressed mood, positive well-
being, self-control, general health and vitality. The Hop-
kins Symptom Checklist (HSCL) is a questionnaire for the
assessment of psychological and somatic complaints [23].
The Profile of Mood States (POMS) is a 32-item question-
naire with subscales depression, anger, fatigue, vigor and
tension [24] and the State-Trait Anxiety Inventory (STAI) is
a questionnaire to assess state and trait anxiety [25]. The
Quality of Life Assessment of Growth Hormone Deficiency in
Adults (QoL-AGHDA) [19] is especially designed to assess
relevant aspects of GHD.
Distinguishing between QoL, well-being and health status
As is pointed out above, QoL is conceived as the total of
psychosocial determinants and physical functioning
assessed from the patient's perspective. We made the QoL
concept operational by "the subjective judgment of the
quality of daily functioning related to psychological or
physical capabilities" and classified the questionnaires
accordingly as QoL. In addition, as well-being is perceived
as feelings of depression, anxiety and energy, and health
status as feelings about physical health we defined well-
being as perceived mental health and health status as per-
ceived physical health. According to the above criteria we
classified the questionnaires into the three categories. If
instruments have multiple domains measuring QoL, well-
being or health status, we classified these domains sepa-
rately. The result of our classification is summarized in
Table 1.
Results
Fifteen studies met our inclusion criteria for analysis of
the effect of GH on patient-reported outcomes and were
included in this meta-analysis. Study characteristics are
shown in Table 2. Total number of patients is 830 and fol-
low-up with a maximum of 24 months was analyzed.
A series of meta-analyses on open-label studies was car-
ried out on our classification of instruments differentiat-
ing QoL, psychological well-being and health status. As
the data were too limited to distinguish between different
treatment lengths we analyzed the effects of pooled treat-
ment durations. GH replacement with an average
duration of 8.6 (±4.0) months (based on 26 d's from 9
studies) improves QoL with a small effect size (p = 0.001;
d = 0.18, 0.07–0.29 [CI]). With regard to psychological
Table 2: Included studies on GH therapy and psychological variables
First author, year [ref] N Mean age (range) 
(years)
Duration therapy 
(months)
Trial design Tests
Ahmad, 2001 [28] 46 Unknown 3 Open QoL-AGHDA
Baum, 1998 [29] 40 Median 51 (24–64) 18 Controlled NHP, PGWB, GHQ, MMPI-2
Burman, 1995 [30] 36 46 (28–57) 9 Controlled NHP, PGWB, HSCL
Carroll, 1997 [31] 38 42.9 6 Controlled NHP, PGWB
Cuneo, 1998 [32] 83 41.2 12 Controlled-open NHP
Degerblad, 1990 [33] 6 20–38 3 Controlled Sjoberg, POMS
Deijen, 1998 [34] 48 27 (19–37) 24 Controlled-open POMS vigor, STAI state, HSCL
Giusti, 1998 [35] 26 51 (21–74) 6 Controlled KSQ, HDS
Hernberg, 2001 [36] 304 M: 50.8
F: 48.6
12 Open QoL-AGHDA, VAS
Murray, 1999 [37] 65 38.7 (17–72) 8 Open QoL-AGHDA, PGWB
Sartorio, 1995 [38] 8 29.6 (25–34) 6 Open Dysphoria, Anxiety
Soares, 1999 [39] 9 39.4 (28–52) 12 Controlled-open HDS, BDI
Stouthart, 2003 [9] 20 21 (17–27) 12 Open QLS, STAI, POMS, SCL-90, HSCL
Wallymahmed, 1997 [40] 30 35 24 Controlled-open NHP, MFQ
Wiren, 1998 [41] 71 45 (19–76) 24 Open NHP, PGWB
BDI = Beck Depression Inventory; GHQ = General Health Questionnaire; HSCL = Hopkins Symptom Check list; HDS = Hamilton Depression 
Scale; MFQ = Mental Fatigue Questionnaire; MMPI-2 = Minnesota Multiphasic Personality Inventory-2; NHP = Nottingham Health Profile; KSQ = 
Kellner Symptom Questionnaire; PGWB = Psychological General Well Being Schedule; POMS = Profile of Mood States; SCL-90 = Symptoms Check 
List-90; Sjöberg = Sjöberg mood questionnaire; STAI = State-Trait Anxiety Inventory; QLS = Quality of Life Scale; QoL-AGHDA = Quality of Life 
Assessment of Growth Hormone Deficiency in Adults; VAS = Visual Analogue Scale.Page 4 of 7
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of 9.2 (±5.1) months (86 d's from 13 studies) an increase
with a medium effect size is found (p < 0.001; d = 0.47,
0.36–0.57 [CI]). Finally, GH replacement with an average
duration of 9.4 (±4.0) months (31 d's from 10 studies)
increases health status with a small effect size (p < 0.001;
d = 0.26, 0.14–0.37 [CI]). Thus, the largest effect is found
for well-being, followed by health status and then Qol
(Figure 1).
Discussion
This present series of meta-analyses evaluated the effects
of GH substitution on psychological parameters in GH
deficient subjects, separately analyzed for QoL, psycho-
logical well-being and health status. Our aim was to exam-
ine whether GH would improve QoL, well-being and
health status differently. Therefore we classified the psy-
chological tests we encountered in the studies as being an
instrument measuring QoL, well-being or health status.
After differentiating QoL from well-being and health sta-
tus we determined the effect sizes obtained from the meta-
analyses on GH replacement. GH replacement appeared
to improve well-being the most, followed by health status
and then QoL. The effect sizes indicate that the effect on
well-being is more than twice as large as that concerning
QoL and nearly twice as large as that concerning health
status. It may be argued that this result may be associated
with differences in the psychometric properties of the
scales for QoL, well-being and health status. However, an
effect size is a standardized, dimensionless number,
which allows the comparison of the results of different
studies or the results of different tests within one study
[26]. In short, effect size is a simple quantitative measure
that provides one useful index of the importance of an
effect. In addition, a distinction can be made between
'small', 'medium' and 'large' effect sizes. A medium effect
size is conceived as one large enough to be visible to the
naked eye [21]. Thus, particularly the medium effect size
of well-being is substantial while the effect sizes of health
status and QoL seem to be of less importance. This sug-
gests that the generally reported effects of GH replacement
on QoL may be overestimated and actually reflect the
effect on psychological well-being. However, as the effect
size index only pertains to statistical effects our data are
not indicative of the clinical relevance of the present
results. In order to determine clinical relevance we should
have been looking at the minimum clinically important
difference for each scale. Unfortunately, such a clinical
determination was not possible because of the variety of
instruments. We can only conclude that a larger effect size
may be associated with a more important clinical effect,
but this needs not necessarily be the case. In contrast, it is
even conceivable that the larger effect size observed for
well-being reflects a smaller clinical relevance than the
small effect size observed for QoL.
Finally, it is important to note that a positive effect of GH
on psychological outcomes has been found mainly in
open studies lacking a control group. The effects of GH
treatment on patient reported outcomes have been com-
pared to placebo in a meta-analysis we performed earlier
on the same database [27]. The purpose of that analysis
was to determine whether GH replacement has any bene-
ficial effect on psychological variables. Therefore, the data
of all questionnaires were pooled disregarding measuring
QoL, well-being or health status. GH treatment effects on
these averaged psychological functions were then com-
pared with placebo. The overall effect of GH treatment
with a median duration of 6 months was found not to be
better than placebo. After reporting these data we decided
to perform the present meta-analysis with a quite different
objective, that is identifying which variable may be most
sensitive to the effects of GH treatment.
It cannot be excluded that the enhanced well-being we
observed in open studies in addition to the absence of a
difference between GH treatment and placebo point to
placebo-effects. The observed improvement in psycholog-
ical outcomes in the open studies can therefore be attrib-
uted to other factors than GH. The attention and care
given to the patients with GHD in the open studies may
improve patient-reported outcomes more substantially
than the contribution of GH itself.
At this point it is important to note that the present meta-
analysis is based only on a selected subgroup of studies,
because a lot of studies did not meet our inclusion criteria.
For instance, in spite of pooling, our sample size appeared
still to be quite small (i.e. 830 patients). In addition, the
variability of patient characteristics, the diversity in study
Average effect sizes for quality of life, health status and well-beingFigure 1
Average effect sizes for quality of life, health status and well-
being.
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publication bias may distort the results. A number of
moderator or confounding variables may have attributed
to the variance in effect sizes. These variables can be
assumed to be sex, age, medial history (radiotherapy),
dose of GH and severity or type of GHD. The limited
amount of data pertaining to these confounders including
the differential treatment effects in patients with either
childhood-onset/adulthood-onset GHD or isolated
GHD/multiple pituitary hormone deficiencies did not
allow to control for these confounders.
The present meta-analysis may therefore have lead to
unjustified conclusions. However, with respect to publica-
tion bias, it is known that especially reports lacking posi-
tive treatment effects are not published. Thus, if such
studies had been published and be part of the meta-anal-
ysis, they would have resulted in smaller effect sizes than
those reported here.
Conclusion
From the present meta-analysis we may conclude that the
psychological effects of GH treatment are not quite clear
yet. A variety of instruments have been used to determine
specific effects on QoL, well-being and health status.
However, up until now the instruments have not been
reliably classified into those measuring QoL, well-being
or health status. The inconsistent classification of psycho-
logical questionnaires may have lead to unjustified
conclusions concerning the psychological effects of GH
therapy. The results of the present meta-analysis based on
generally accepted definitions of these concepts indicate
that the effects of GH treatment are most obvious with
respect to well-being, followed by health status and QoL.
It may thus well be true that the frequently reported effects
of GH on QoL are overvalued. Therefore, to get more
insight into the precise nature of the psychological effects
of GH therapy we recommend that in future studies more
uniform classifications of psychological outcomes should
be used.
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